The World Health Organization has approved the Novavax vaccine against coronavirus developed for emergency use by the Serum Institute of India. According to Report.ge, Bloomberg writes about it.
The publication notes that the approval of the Indian vaccine will help speed up vaccination in low-income countries. Novavax will supply WHO's COVAX platform with over 1.1 billion doses of the vaccine.
A European regulator is currently testing the Novavax vaccine. The vaccine is expected to be approved by the European Medicines Agency in the coming days.
In June 2021, the company Novavax announced that its vaccine had achieved 90 percent efficacy in clinical trials. In addition, according to the manufacturer, Nuvaxovid also protects against virus mutations and complications of COVID-19 disease.
